Responses
Regular and young investigator award abstracts
Combination immunotherapies
441 Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized
Compose a Response to This Article
Other responses
No responses have been published for this article.
